Drug Trial Radar · NCT06603623
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
647
Actual
Start
Oct 10, 2024
Primary completion
Mar 24, 2025
Study completion Mar 28, 2025
Sponsor
- Lead sponsor
- Biohaven Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
Conditions
- Migraine
Interventions
BHV-2100Drug
BHV-2100 75mg
BHV-2100Drug
BHV-2100 150 mg
PlaceboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Freedom From Pain at 2 Hours Post-doseTime frame: 2 hours post-dose
- Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-doseTime frame: 2 hours post-dose
Locations
60 sites in 1 country. Site status is shown where the registry gives one.
MD First Research
Gilbert, Arizona
WR-PRI, LLC (Encino)
Encino, California
Cenexel CNS Los Alamitos
Los Alamitos, California
Clinical Research Institute
Los Angeles, California
WR-PRI, LLC (Newport Beach)
Newport Beach, California
Cenexel CIT IE
Riverside, California
Hasbani Neurology
New Haven, Connecticut
Ki Health Partners DBA/ New England Institute for Clinical Research
Stamford, Connecticut
Green Leaf Clinical Trials
Jacksonville, Florida
WR-MSRA (Multi-Specialty Research Associates)
Lake City, Florida
AppleMed Research Group
Miami, Florida
Ideal Research
Pembroke Pines, Florida
ForCare Clinical Research
Tampa, Florida
Premier Research Instiute
West Palm Beach, Florida
NeuroTrials Research, Inc.
Atlanta, Georgia
Velocity Clinical Research, Savannah
Savannah, Georgia
Chicago Headache Center & Research Center
Chicago, Illinois
Healthcare Research Network II, LLC
Flossmoor, Illinois
Velocity Clinical Research, Sioux City
Sioux City, Iowa
Integrated Clinical Trials Services
West Des Moines, Iowa
Collective Medical Research
Overland Park, Kansas
L-MARC Research Center
Louisville, Kentucky
Crescent City Headache & Neurology
Chalmette, Louisiana
DelRicht Research
New Orleans, Louisiana
Velocity Clinical Research, Rockville
Rockville, Maryland
Boston Clinical Trials
Boston, Massachusetts
Neurology Center of New England PC
Foxborough, Massachusetts
MedVadis Research Corp
Waltham, Massachusetts
Mass Institute of Clinical Research
Westborough, Massachusetts
Michigan Head Pain and Neurological Institute
Ann Arbor, Michigan
Quest Research Institute
Farmington Hills, Michigan
Clinical Research Institute
Minneapolis, Minnesota
StudyMedrix Research
City of Saint Peters, Missouri
Alliance for Multispecialty Research - Kansas City
Kansas City, Missouri
Clinvest Research
Springfield, Missouri
WR-CRNC (Wake Research)
Las Vegas, Nevada
ActivMed Practices & Research-Portsmouth/Pease
Portsmouth, New Hampshire
Albuquerque Clinical Trials
Albuquerque, New Mexico
Fieve Clinical Research, Inc.
New York, New York
Rochester Clinical Research
Rochester, New York
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.